Trial Search Results

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. the investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Botulinum Toxin Type A
  • Drug: Saline




Inclusion Criteria:

   - Moderate to severe pain (greater than 2/10) of duration more than 6 months despite
   previous therapy, excluding botox injection

   - The patient exhibits at least 80% pain relief following injection of local anesthetic
   subcutaneously into scar as assessed by change in NRS

   - Patient reports more than 3 weeks of greater than 50% pain relief from previous botox

   - The patient reports the presence of hyperalgesia, allodynia, dysesthesia, or
   hypoesthesia surrounding the scar in the absence of the botox injection

   - Age 18-100

   - Ability to read, write, and converse in English, provide informed consent, and follow
   study procedures

Exclusion Criteria:

   - Any neuromuscular disorder such as myasthenia gravis, eaton lambert, muscular

   - Any ongoing legal action related to their pain

   - Allergy to local anesthetics

   - Any ongoing disability claim

   - Currently being treated for any severe psychiatric disorder, including anxiety or

   - History of any adverse reaction to botulinum toxin

   - History of botulism

   - Untreated infection

   - Coagulopathy

   - (Females) - positive pregnancy test

   - Surgery in the last 6 months

Ages Eligible for Study

18 Years - 100 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Charlie Wang
Not Recruiting